43-residue N-terminally acetylated peptide
Thymosin beta-4 — evidence
What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.
Evidence overview
No evidence records in this file yet.
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Regulatory notes
No FDA-approved product
- No approved drug product exists in Drugs@FDA.
- FDA's compounding tables list the fragment “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”, not the full-length peptide.
- WADA's entry names thymosin-β4 and its derivatives together, so the parent peptide and the fragment fall under the same listing.
Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.
No records in this file match the current filter. That is an empty result, not a finding about the compound.
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built